Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL0911 in adult chronic primary ITP (Phase III)
CTR20191489Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of QL0911 in immune thrombocytopenia (ITP), sponsored by Qilu Pharmaceutical. Started Aug 2019; status: completed.
02
Drugs
QL0911
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20191489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191489.